
	Search

Web

Site

Get our free newsletter


	Special Offers


	Health Tools


	Acid Reflux Revention

	Info About The Large Intestine

	The Stomach and Small Intestine

	Check Symptoms for Acid Reflux

	Check IBD Symptoms

	The Facts About Infant Intestines

	Quiz: The Digestive System

	Ask A Questions About IBD

	Causes of Acid Reflux

	Ask A Question About Digestion


	Featured Conditions


	Acid Reflux

	Acid Reflux

	Inflammatory Bowel Disease

	Diet & Exercise

	Cholesterol

	Diet & Exercise

	Cholesterol

	Inflammatory Bowel Disease


	Resources

	Healthscout News

	3D Health Animations

	Health Videos

	Quizzes & Tools

	Health Encyclopedia

	Library & Communities

	News Archive

	Drug Library


	Find a Therapist

Enter City or Zip Code:
Powered by Psychology Today


	Channels

Drug Description	Side Effects & Drug Interactions	Warnings & Precautions	Additional Info
Clinical Pharmacology	Overdosage & Contraindications	Indications & Dosage	Patient Info

Ortho-Novum

[Norethindrone/Ethinyl Estradiol]

(See Discussion of Dose-Related Risk of Vascular Disease from Oral Contraceptives.)

HOW SUPPLIED

ORTHO-NOVUM 7/ 7/ 7 Tablets are available in a DIALPAK Tablet Dispenser (NDC 0062-1781-15) containing 28 tablets, as follows: 7 white tablets (0.5 mg norethindrone and 0.035 mg ethinyl estradiol), 7 light peach tablets (0.75 mg norethindrone and 0.035 mg ethinyl estradiol, 7 peach tablets (1 mg norethindrone and 0.035 mg ethinyl estradiol) and 7 green tablets containing inert ingredients.

Text Continues Below

The white tablets are unscored with "Ortho" and "535" debossed on each side; the light peach tablets are unscored with "Ortho" and "75" debossed on each side; the peach tablets are unscored with "Ortho" and "135" debossed on each side and the green tablets are unscored with "Ortho" debossed on each side. ORTHO-NOVUM 7/ 7/ 7 is available for clinic usage in a VERIDATE Tablet Dispenser (unfilled) and VERIDATE Refills (NDC 0062-1781-20).

ORTHO-NOVUM 10/ 11 Tablets are available in a DIALPAK Tablet Dispenser (NDC 0062-1771-15) contain-ing 28 tablets, as follows: 10 white tablets (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) 11 peach tablets (1 mg norethindrone and 0.035 mg ethinyl estradiol) and 7 green tablets containing inert ingredients.
The white tablets are unscored with "Ortho" and "535" debossed on each side; the peach tablets are unscored with "Ortho" and "135" debossed on each side and the green tablets are unscored with "Ortho" debossed on each side. ORTHO-NOVUM 1/ 35 Tablets are available in a DIALPAK Tablet Dispenser (NDC 0062-1761-15) containing 28 tablets, as follows: 21 peach tablets (1 mg norethindrone and 0.035 mg ethinyl estradiol) and 7 green tablets containing inert ingredients.
The peach tablets are unscored with "Ortho" and "135" debossed on each side and the green tablets are unscored with "Ortho" debossed on each side.

ORTHO-NOVUM 1/ 35 is available for clinic usage in a VERIDATE Tablet Dispenser (unfilled) and VERIDATE Refills (NDC 0062-1761-20).
MODICON Tablets are available in a DIALPAK Tablet Dispenser (NDC 0062-1714-15) containing 28 tablets, as follows: 21 white tablets (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) and 7 green tablets containing inert ingredients.
The white tablets are unscored with "Ortho" and "535" debossed on each side and the green tablets are unscored with "Ortho" debossed on each side.

MODICON is available for clinic usage in a VERIDATE Tablet Dispenser (unfilled) and VERIDATE Refills (NDC 0062-1714-20).
� only

REFERENCES
1. Trussel J. Contraceptive efficacy. In Hatcher RA, Trussel J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998, in press.

2. Stadel BV, Oral contraceptives and cardiovascular disease. (Pt. 1). N Engl J Med 1981; 305: 612-618.

3. Stadel BV, Oral contraceptives and cardiovascular disease. (Pt. 2). N Engl J Med 1981; 305: 672-677.

4. Adam SA, Thorogood M. Oral contraception and myocardial infarction revisited: the effects of new prepara-tions and prescribing patterns. Br J Obstet Gynaecol 1981; 88: 838-845.

5. Mann JI, Inman WH. Oral contraceptives and death from myocardial infarction. Br Med J 1975; 2( 5965): 245-248.

6. Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J 1975; 2( 5956): 241-245.

7. Royal College of General Practitioners' Oral Contraception Study: further analyses of mortality in oral contraceptive users. Lancet 1981; 1: 541-546.

8. Slone D, Shapiro S, Kaufman DW,
Rosenberg L, Miettinen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981; 305: 420-424.

9. Vessey MP. Female hormones and vascular disease � an epidemiological overview. Br J Fam Plann 1980; 6 (Supplement): 1-12.

10. Russell-Briefel RG, Ezzati TM, Fulwood R, Perlman JA, Murphy RS. Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Prevent Med 1986; 15: 352-362.

11. Goldbaum GM, Kendrick JS, Hogelin GC, Gentry EM. The relative impact of smoking and oral contraceptive use on women in the United States. JAMA 1987; 258: 1339-1342.

12. Layde PM, Beral V. Further analyses of mortality in oral contraceptive users; Royal College of General Practitioners' Oral Contraception Study. (Table 5) Lancet 1981; 1: 541-546.

13. Knopp RH. Arteriosclerosis risk: the roles of oral contraceptives and postmenopausal estrogens. J Reprod Med 1986; 31( 9) (Supplement): 913-921.

14. Krauss RM, Roy S, Mishell DR, Casagrande J, Pike MC. Effects of two low-dose oral contra-ceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am J Obstet 1983; 145: 446-452.

15. Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B. Effect of estrogen/ progestin potency on lipid/ lipoprotein cholesterol. N Engl J Med 1983; 308: 862-867.

16. Wynn V, Niththyananthan R. The effect of progestin in combined oral contraceptives on serum lipids with special ref-erence to high density lipoproteins. Am J Obstet Gynecol 1982; 142: 766-771.

17. Wynn V, Godsland I. Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med 1986; 31( 9)( Supplement): 892-897.

18. LaRosa JC. Atherosclerotic risk factors in cardiovascular disease. J Reprod Med 1986; 31( 9)( Supplement): 906-912.

19. Inman WH, Vessey MP. Investigation of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br Med J 1968; 2( 5599): 193-199.

20. Maguire MG, Tonascia J, Sartwell PE, Stolley PD, Tockman MS. Increased risk of thrombosis due to oral contraceptives: a further
report. Am J Epidemiol 1979; 110( 2): 188-195.

21. Petitti DB, Wingerd J, Pellegrin F, Ramacharan S. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242: 1150-1154.

22. Vessey MP, Doll R. Investigation of relation between use of oral contracep-tives and thromboembolic disease. Br Med J 1968; 2( 5599): 199-205.

23. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J 1969; 2( 5658): 651-657.

24. Porter JB, Hunter JR, Danielson DA, Jick H, Stergachis A. Oral contraceptives and non-fatal vascular disease � recent experience. Obstet Gynecol 1982; 59( 3): 299-302.

25. Vessey M, Doll R, Peto R, Johnson B, Wiggins P. A long-term follow-up study of women using different methods of contraception:
an interim report. J Biosocial Sci 1976; 8: 375-427.

26. Royal College of General Practitioners: Oral Contraceptives, venous thrombosis, and varicose veins. J Royal Coll Gen Pract 1978; 28: 393-399.

27. Collaborative Group for the Study of Stroke in Young Women: Oral contraception and increased risk of cerebral ischemia or throm-bosis. N Engl J Med 1973; 288: 871-878.

28. Petitti DB, Wingerd J. Use of oral contraceptives, cigarette smok-ing,
and risk of subarachnoid hemorrhage. Lancet 1978; 2: 234-236.

29. Inman WH. Oral contraceptives and fatal subarachnoid hemorrhage. Br Med J 1979; 2( 6203): 1468-1470.

30. Collaborative Group for the Study of Stroke in Young Women: Oral Contraceptives and stroke in young women: associated risk factors. JAMA 1975; 231: 718-722.

31. Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970; 2: 203-209.

32. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 35-mcg oestrogen preparations. Br Med J 1980; 280( 6224): 1157-1161.

33. Kay CR. Progestogens and arterial disease � evidence from the Royal College of General Practitioners' Study. Am J Obstet Gynecol 1982; 142: 762-765.

34. Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J Royal Coll Gen Pract 1983;
33: 75-82.

35. Ory HW. Mortality associated with fertility and fertility control: 1983. Family Planning Perspectives 1983; 15: 50-56.

36. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of breast cancer. N Engl J Med 1986; 315: 405-411.

37. Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in
young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983; 2: 926-929.

38. Paul C, Skegg DG, Spears GFS, Kaldor JM. Oral contraceptives and breast cancer: A national study. Br Med J 1986; 293: 723-725.

39. Miller DR, Rosenberg L, Kaufman DW, Schottenfeld D, Stolley PD, Shapiro S. Breast cancer risk in relation to early oral contraceptive use. Obstet Gynecol 1986; 68: 863-868.

40. Olsson H, Olsson ML, Moller TR, Ranstam J, Holm P. Oral contraceptive use and breast cancer in young women in Sweden (letter). Lancet 1985; 1( 8431): 748-749.

41. McPherson K, Vessey M, Neil A, Doll R, Jones L, Roberts M. Early contraceptive use and breast cancer: Results of another case-control study. Br J Cancer 1987; 56: 653-660.

42. Huggins GR, Zucker PF. Oral contraceptives and neoplasia: 1987 update. Fertil Steril 1987; 47: 733-761.

43. McPherson K, Drife JO. The pill and breast cancer: why the uncertainty? Br Med J 1986; 293: 709-710.

44. Shapiro S. Oral contraceptives � time to take stock. N Engl J Med 1987; 315: 450-451.

45. Ory H, Naib Z, Conger SB, Hatcher RA, Tyler CW. Contraceptive choice and prevalence of cervical dysplasia and carcinoma in situ. Am J Obstet Gynecol 1976; 124: 573-577.

46. Vessey MP, Lawless M, McPherson K, Yeates D. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 1983; 2: 930.

47. Brinton LA, Huggins GR, Lehman HF, Malli K, Savitz DA, Trapido E, Rosenthal J, Hoover R. Long term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 1986; 38: 339-344.

48. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Br Med J 1985; 290: 961-965

49. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW. Epidemiology of hepatocellular adenoma: the role of oral contraceptive use.
JAMA 1979; 242: 644-648.

50. Bein NN, Goldsmith HS. Recurrent massive hemorrhage from benign hepatic tumors secondary to oral contraceptives. Br J Surg 1977; 64: 433-435.

51. Klatskin G. Hepatic tumors: pos-sible relationship to use of oral contraceptives. Gastroenterology 1977; 73: 386-394.

52. Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC. Hepatocellular carcinoma and oral contraceptives. Br J Cancer 1983; 48: 437-440.

53. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and he-patocellular carcinoma. Br Med J 1986; 292: 1355-1357.

54. Forman D, Vincent TJ, Doll R. Cancer of the liver
and oral contraceptives. Br Med J 1986; 292: 1357-1361.

55. Harlap S, Eldor J. Births following oral contra-ceptive failures. Obstet Gynecol 1980; 55: 447-452.

56. Savolainen E, Saksela E, Saxen L. Teratogenic haz-ards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 1981; 140: 521-524.

57. Janerich DT, Piper JM, Glebatis DM. Oral contraceptives and birth defects. Am J Epidemiol 1980; 112: 73-79.

58. Ferencz C, Matanoski GM, Wilson PD, Rubin JD, Neill CA, Gutberlet R. Maternal hormone therapy and congenital heart disease. Teratology 1980; 21: 225-239.

59. Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979; 109: 433-439.

60. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet 1973; 1: 1399-1404.

61. Royal College of General Practitioners: Oral contraceptives and health. New York, Pittman 1974.

62. Layde PM, Vessey MP, Yeates D. Risk of gallbladder disease: a cohort study of young women attending family planning clinics. J Epidemiol Community Health 1982; 36: 274-278.

63. Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO): Prevalence of gallstone disease in an Italian adult female popu-lation. Am J Epidemiol 1984; 119: 796-805.

64. Storm BL, Tamragouri RT, Morse ML, Lazar EL, West SL, Stolley
PD, Jones JK. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39: 335-341.

65. Wynn V, Adams PW, Godsland IF, Melrose J, Niththyananthan R, Oakley NW, Seedj A. Comparison of effects of different combined oral contraceptive formulations on carbohydrate and lipid me-tabolism. Lancet 1979; 1: 1045-1049.

66. Wynn V. Effect of progesterone and progestins on carbohydrate me-tabolism. In: Progesterone and Progestin. Bardin CW, Milgrom E, Mauvis-Jarvis P. eds. New York, Raven Press, 1983; pp. 395-410.

67. Perlman JA, Roussell-Briefel RG, Ezzati TM, Lieberknecht G. Oral glucose tolerance and the potency of oral contraceptive progestogens. J Chronic Dis 1985; 38: 857-864.

68. Royal College of General Practitioners' Oral Contraception Study: Effect on hypertension and benign breast disease of progesto-gen
component in combined oral contraceptives. Lancet 1977; 1: 624.

69. Fisch IR, Frank J. Oral contracep-tives and blood pressure. JAMA 1977; 237: 2499-2503.

70. Laragh AJ. Oral contraceptive induced hypertension � nine years later. Am J Obstet Gynecol 1976; 126: 141-147.

71. Ramcharan S, Peritz E, Pellegrin FA, Williams WT. Incidence of hypertension in the Walnut Creek Contraceptive Drug Study cohort: In: Pharmacology of steroid contraceptive drugs. Garattini S, Berendes HW. Eds. New York, Raven Press, 1977; pp. 277-288, (Monographs of the Mario Negri Institute for Pharmacological Research Milan.)

72. Stockley I. Interactions with oral contraceptives. J Pharm 1976; 216: 140-143.

73. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral con-traceptive use and the risk of ovarian cancer. JAMA 1983; 249: 1596-1599.

74. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257: 796-800.

75. Ory HW. Functional ovarian cysts and oral contraceptives: negative association confirmed surgically. JAMA 1974; 228: 68-69.

76. Ory HW, Cole P, MacMahon B, Hoover R. Oral contraceptives and reduced risk of benign breast disease. N Engl J Med 1976; 294: 419-422.

77. Ory HW. The noncontraceptive health benefits from oral contraceptive use. Fam Plann Perspect 1982; 14: 182-184.

78. Ory HW, Forrest JD, Lincoln R. Making choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, 1983; p. 1.

79. Schlesselman J, Stadel BV, Murray P, Lai S. Breast cancer in relation to early use of oral contraceptives. JAMA 1988; 259: 1828-1833.

80. Hennekens CH, Speizer FE, Lipnick RJ, Rosner B, Bain C, Belanger C, Stampfer MJ, Willett W, Peto R. A case-control study of oral contraceptive use and breast cancer. JNCI 1984; 72: 39-42.

81. LaVecchia C, Decarli A, Fasoli M, Franceschi S, Gentile A, Negri E, Parazzini F, Tognoni G. Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. Br J Cancer 1986; 54: 311-317.

82. Meirik O, Lund E, Adami H, Bergstrom, Christoffersen T, Bergsjo P. Oral contraceptive use and breast cancer in young women. A Joint National Case-control study in Sweden and Norway. Lancet 1986; 11: 650-654.

83. Kay CR, Hannaford PC. Breast cancer and the pill � A further report from the Royal College of General Practitioners' oral contraception study. Br J Cancer 1988; 58: 675-680.

84. Stadel BV, Lai S, Schlesselman JJ, Murray P. Oral contraceptives and pre-menopausal breast cancer in nulliparous women. Contraception 1988; 38: 287-299.

85. Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S. Breast cancer before age 45 and oral contraceptive use:
New Findings. Am J Epidemiol 1989; 129: 269-280.

86. The UK National Case-Control Study Group, Oral con-traceptive use and breast cancer risk in young women. Lancet 1989; 1: 973-982.

87. Schlesselman JJ. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 1989; 40: 1-38.

88. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 1989; 59: 613-617.

89. Jick SS, Walker AM, Stergachis A, Jick H. Oral contraceptives and breast cancer. Br J Cancer 1989; 59: 618-621.

90. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiolog-ical studies. Lancet 1996; 347: 1713-1727.

91. Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S. Oral Contraceptive Use and Liver Cancer. Am J Epidemiol 1989; 130: 878-882.

92. Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. Geneva, WHO, Family and Reproductive Health, 1996.

Page: << Prev | 1 | 2 | 3 | 4 | 5


About The HealthScout Network Contact Us Copyright � 2001-2009. The HealthCentralNetwork, Inc. All rights reserved. Privacy Policy: Updated as of April 1, 2009 Terms of Service
Advertising Policy